摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

9-fluoro-2-[(1-oxidopyridin-2-yl)thio]-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one | 868994-85-8

中文名称
——
中文别名
——
英文名称
9-fluoro-2-[(1-oxidopyridin-2-yl)thio]-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one
英文别名
15-Fluoro-4-(1-oxidopyridin-1-ium-2-yl)sulfanyl-3,5,10-triazatetracyclo[11.4.0.02,6.07,12]heptadeca-1(13),2(6),4,7(12),8,14,16-heptaen-11-one
9-fluoro-2-[(1-oxidopyridin-2-yl)thio]-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one化学式
CAS
868994-85-8
化学式
C19H11FN4O2S
mdl
——
分子量
378.386
InChiKey
AZLHDASFGLFXAK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    27
  • 可旋转键数:
    2
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    109
  • 氢给体数:
    2
  • 氢受体数:
    5

文献信息

  • [EN] JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES<br/>[FR] INHIBITEURS DES JANUS KINASES POUR LE TRAITEMENT DU SYNDROME DE L'OEL SEC ET AUTRES MALADIES DE L'OEL
    申请人:INCYTE CORP
    公开号:WO2010039939A1
    公开(公告)日:2010-04-08
    Methods, kits, and compositions for treating dry eye disorders and other related eye diseases are provided, wherein the methods, kits, and compositions utilize a JAK inhibitor.
    本发明提供了用于治疗干眼症和其他相关眼部疾病的方法、试剂盒和组合物,其中所述方法、试剂盒和组合物利用JAK抑制剂
  • JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES
    申请人:Incyte Corporation
    公开号:US20170087158A1
    公开(公告)日:2017-03-30
    The present application relates to Janus kinase (JAK) inhibitors, including 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, for the treatment of a dry eye disorder or ameliorating a particular symptom of a dry eye disorder, such as eye discomfort, visual disturbance, tear film instability, tear hyperosmolarity, and inflammation of the ocular surface, as well as kits and compositions, including topical compositions, related thereto.
    本申请涉及Janus激酶(JAK)抑制剂,包括3-环戊基-3- [4-(7H-吡咯[2,3-d]嘧啶-4-基)-1H-吡唑-1-基]丙腈,用于治疗干眼症或改善干眼症的特定症状,如眼部不适,视觉障碍,泪膜不稳定,泪液高渗性和眼表炎症,以及相关的套件和组合物,包括局部组合物。
  • Tetracyclic inhibitors of Janus kinases
    申请人:Rodgers D. James
    公开号:US20060106020A1
    公开(公告)日:2006-05-18
    The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer.
    本发明提供了一种调节Janus激酶活性的化合物,可用于治疗与Janus激酶活性相关的疾病,例如免疫相关疾病和癌症。
  • TETRACYCLIC INHIBITORS OF JANUS KINASES
    申请人:Rodgers James D.
    公开号:US20090215766A1
    公开(公告)日:2009-08-27
    The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer.
    本发明提供了一种可以调节Janus激酶活性的化合物,这些化合物可用于治疗与Janus激酶活性相关的疾病,例如免疫相关疾病和癌症。
  • METHOD OF TREATING MUSCULAR DEGRADATION
    申请人:Rigel Pharmaceuticals, Inc.
    公开号:US20130310340A1
    公开(公告)日:2013-11-21
    A method for treating muscular deterioration is disclosed. Also disclosed are embodiments of a compound, and compositions comprising the compound, for inhibiting muscular deterioriation, including atrophy, dystrophy, and cachexia, such as may result from ventilation.
查看更多